Expression of Genes Encoding Cell Motility Proteins during Progression of Head and Neck Squamous Cell Carcinoma
- Authors: Cheremisina O.V.1, Novikov V.A.1, Choinzonov E.L.1,2, Kakurina G.V.1, Kondakova I.V.1, Spirina L.V.1,2, Kolegova E.S.1, Shashova E.E.1
-
Affiliations:
- Research Institute of Oncology, Tomsk National Research Medical Center, Russian Academy of Sciences
- Siberian State Medical University
- Issue: Vol 166, No 2 (2018)
- Pages: 250-252
- Section: Article
- URL: https://journal-vniispk.ru/0007-4888/article/view/240935
- DOI: https://doi.org/10.1007/s10517-018-4325-1
- ID: 240935
Cite item
Abstract
The model of head and neck squamous cell carcinoma (HNSCC) was used to study the expression of genes encoding actin-binding proteins depending on the type of cell motility. The expression of SNAIL1 and CAPN2 mRNA in HNSCC tissue was higher than in specimens of dysplastic epithelium of the larynx and hypopharynx, which can be explained by activation of mesenchymal and amoeboid types of cell motility. In biopsy material of HNSCC patients with T1-2N0M0, expression of genes responsible for actin-binding proteins differed from that of patients with pretumor pathology of the larynx and hypopharynx: expression of FSCN was lower, while expressions of EZR and CAP1 were higher. The data attest that progression of HNSCC is associated with activation of both types of cell motility and with the changes in the expression of mRNA encoding cell motility proteins.
About the authors
O. V. Cheremisina
Research Institute of Oncology, Tomsk National Research Medical Center, Russian Academy of Sciences
Email: kakurinagv@oncology.tomsk.ru
Russian Federation, Moscow
V. A. Novikov
Research Institute of Oncology, Tomsk National Research Medical Center, Russian Academy of Sciences
Email: kakurinagv@oncology.tomsk.ru
Russian Federation, Moscow
E. L. Choinzonov
Research Institute of Oncology, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University
Email: kakurinagv@oncology.tomsk.ru
Russian Federation, Moscow; Tomsk
G. V. Kakurina
Research Institute of Oncology, Tomsk National Research Medical Center, Russian Academy of Sciences
Author for correspondence.
Email: kakurinagv@oncology.tomsk.ru
Russian Federation, Moscow
I. V. Kondakova
Research Institute of Oncology, Tomsk National Research Medical Center, Russian Academy of Sciences
Email: kakurinagv@oncology.tomsk.ru
Russian Federation, Moscow
L. V. Spirina
Research Institute of Oncology, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University
Email: kakurinagv@oncology.tomsk.ru
Russian Federation, Moscow; Tomsk
E. S. Kolegova
Research Institute of Oncology, Tomsk National Research Medical Center, Russian Academy of Sciences
Email: kakurinagv@oncology.tomsk.ru
Russian Federation, Moscow
E. E. Shashova
Research Institute of Oncology, Tomsk National Research Medical Center, Russian Academy of Sciences
Email: kakurinagv@oncology.tomsk.ru
Russian Federation, Moscow
Supplementary files
